First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report

por Hamai, Kosuke, Tanahashi, Hiroki, Ueno, Sayaka, Konishi, Hanae, Matsumura, Mirai, Nomura, Akio, Nakamoto, Kanako, Isoyama, Shoko, Tanimoto, Takuya, Shoda, Hiroyasu, Ishikawa, Nobuhisa
Publicado 2020

Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer

por Watari, Naokazu, Yamaguchi, Kakuhiro, Terada, Hiroaki, Hamai, Kosuke, Masuda, Ken, Nishimura, Yoshifumi, Sakamoto, Shinjiro, Masuda, Takeshi, Horimasu, Yasushi, Miyamoto, Shintaro, Nakashima, Taku, Iwamoto, Hiroshi, Shoda, Hiroyasu, Ishikawa, Nobuhisa, Fujitaka, Kazunori, Miyazaki, Kozue, Miyata, Yoshihiro, Hamada, Hironobu, Awai, Kazuo, Hattori, Noboru
Publicado 2022

Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally...

por Daido, Wakako, Masuda, Takeshi, Imano, Nobuki, Matsumoto, Naoko, Hamai, Kosuke, Iwamoto, Yasuo, Takayama, Yusuke, Ueno, Sayaka, Sumii, Masahiko, Shoda, Hiroyasu, Ishikawa, Nobuhisa, Yamasaki, Masahiro, Nishimura, Yoshifumi, Kawase, Shigeo, Shiota, Naoki, Awaya, Yoshikazu, Suzuki, Tomoko, Kitaguchi, Soichi, Fujitaka, Kazunori, Nagata, Yasushi, Hattori, Noboru
Publicado 2022

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resec...

por Tanizaki, Junko, Kuroda, Hiroaki, Yokoyama, Toshihide, Takahama, Makoto, Shoda, Hiroyasu, Nakamura, Atsushi, Kitamura, Yoshitaka, Mamesaya, Nobuaki, Kadota, Yoshihisa, Sawa, Kenji, Okishio, Kyoichi, Okada, Morihito, Suminaka, Chihiro, Noda, Kenta, Sakai, Kazuko, Chiba, Yasutaka, Nishio, Kazuto, Chamoto, Kenji, Honjo, Tasuku, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko, Hayashi, Hidetoshi
Publicado 2023